• Genentech to Extend Payment Terms for LUCENTIS® (ranibizumab injection)

    Biotech giant is the second company to work with the American Academy of Ophthalmology to support patients and ophthalmologists during COVID-19 crisis 

    SAN FRANCISCO, Calif. – In response to the COVID-19 pandemic, Genentech today announced that it will temporarily extend physician payment terms for Lucentis purchases from authorized distributors to 120 days. Genentech is working to implement these new, temporary payment terms for purchases from April 1, 2020, as well as retroactively for Lucentis purchased on or after March 1, 2020.

    Practices may be temporarily eligible for payment terms of up to 120 days (previously 60 days), subject to distributor qualification.

    Company officials say they will evaluate these temporary payment terms as the pandemic evolves and will update the program as needed.

    Please contact your specialty distributor with questions or to verify these new terms.

    For the Academy’s latest coronavirus updates for ophthalmologists, go to aao.org/coronavirus

     

    About the American Academy of Ophthalmology

    The American Academy of Ophthalmology is the world’s largest association of eye physicians and surgeons. A global community of 32,000 medical doctors, we protect sight and empower lives by setting the standards for ophthalmic education and advocating for our patients and the public. We innovate to advance our profession and to ensure the delivery of the highest-quality eye care. Our EyeSmart® program provides the public with the most trusted information about eye health. For more information, visit aao.org.